Mobile Site ›

What the FDA Relabeling of Abacavir Means for You and Your Patient



Subscribe

Receive notification when new Hot Topics are published:

Information for Patients5

Slide 19

November 2008

Providers can also inform the patients that they are at lower risk of a serious hypersensitivity reaction when taking abacavir, however, hypersensitivity reaction can still occur because a negative test result is not 100% predictive.

Finally, patients with unknown HLA-B*5701 status should be tested prior to reinitiating abacavir treatment, even if they tolerated abacavir previously.

Information for Patients5

 


Jump to section:


Key